INVESTIGATIONAL AGENTS [phsu]
Pancreatic beta Cells [cell]
Failure [ftcn]
Type 2 Diabetes [dsyn]
Insulin Resistance [patf]
Reduced [qlco]
insulin secretion [celf]
Hyperglycaemia [dsyn]
Then [tmco]
???lead [elii, hops]
Diabetic Complications [patf]
Retinopathy [dsyn]
Neuropathy [dsyn]
Nephropathy [dsyn]
Cardiovascular disease [dsyn]
Insulin Resistance [patf]
Present [qnco]
progression [patf]
Now [tmco]
Accepted [qlco]
Deterioration [phpr]
Insulin [aapp, horm, phsu]
Secretory [celf]
function [phsf]
???lead [elii, hops]
Hyperglycaemia [dsyn]
reduction [npop]
insulin secretion [celf]
Type 2 Diabetes [dsyn]
Islet cell [bpoc]
P NOS [aapp, imft]
dysfunction [ftcn]
interventions [hlca]
Maintain [acty]
Normal [qlco]
function [phsf]
Pancreatic beta Cells [cell]
treatment [ftcn]
Type 2 Diabetes [dsyn]
SO [geoa]
plasma glucose level [lbtr]
Maintained [ftcn]
Normal Range [qnco]
Recently [tmco]
Compound [qlco]
Beta cell [cell]
Failure [ftcn]
Therapies [topp]
Type 2 Diabetes [dsyn]
Plasma glucose [lbpr]
Metformin [orch, phsu]
Insulin Sensitivity [patf]
Thiazolidinediones [orch, phsu]
function [phsf]
New Agents [clas]
Therapeutic [topp]
Design [acty]
Levels [qlco]
Glucagon-Like Peptide 1 [aapp]
insulin secretion [celf]
APPEAR [qlco]
Islet cell [bpoc]
Beta [plnt]
Mass [fndg]
Presented [idcn]
Future [tmco]
Drug Therapy [topp]
Design [acty]
PREVENT [phsu]
P cell [cell]
Failure [ftcn]
Target [ftcn]
formation [biof]
Glycation End Products, Advanced [bacs, orch]
Oxidative [ftcn]
Endoplasmic Reticulum Stress [comd]
